Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...